Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 72Multiple Myeloma 70Leukemia, Myeloid, Acute 70Lymphoma, Large B-Cell, Diffuse 61Lymphoma, Non-Hodgkin 58Leukemia, Lymphocytic, Chronic, B-Cell 57Lymphoma 56Melanoma 52Leukemia 52Breast Neoplasms 49Burkitt Lymphoma 48Myelodysplastic Syndromes 44Recurrence 41Lymphoma, Follicular 41Lymphoma, B-Cell 38Lymphoma, Mantle-Cell 37Ovarian Neoplasms 32Neuroblastoma 32Lymphoma, B-Cell, Marginal Zone 27Sarcoma 26Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Hodgkin Disease 24Neoplasm Metastasis 23Triple Negative Breast Neoplasms 18Carcinoma, Renal Cell 18Neoplasms, Plasma Cell 17Hematologic Neoplasms 17Leukemia, Myelomonocytic, Chronic 16Colorectal Neoplasms 16

Interventions

fludarabine 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Polyradiculoneuropathy, Chronic Inflammatory Demyelinating × Cyclophosphamide × Clear all
NCT07526493 2026-05-12

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Tongji Hospital

Phase 1 Recruiting
6 enrolled

Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT07304154 2026-04-21

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Gilead Sciences

Phase 1 Recruiting
52 enrolled

Multiple Sclerosis, Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡